ubrogepant基于之前曝光的效果和对药物的反应:事后分析。

文章的细节

引用

复制到剪贴板

Blumenfeld,戈德比PJ Dodick DW,哈钦森,刘C,芬尼根M, Trugman JM, Szegedi

ubrogepant基于之前曝光的效果和对药物的反应:事后分析。

头痛。2021年3月,61 (3):422 - 429。doi: 10.1111 / head.14089。Epub 2021年3月22日。

PubMed ID

33749826 (在PubMed

]

文摘

目的:确定的潜在功效ubrogepant基于历史经验的急性治疗偏头痛的药物。背景:虽然药物改善偏头痛治疗,其疗效和耐受性可能会限制一些个人的效用。Ubrogepant是小分子,口服降钙素相关基因肽受体拮抗剂通过美国食品和药物管理局对急性治疗偏头痛的成年人。方法:本池的事后分析。关键试验的数据实现I和II,相同设计,随机、双盲、3阶段,单一攻击试验ubrogepant史的成人偏头痛有/没有光环,检查ubrogepant 50毫克与安慰剂的疗效和耐受性基于参与者的历史经验与药物:曲普坦响应者,triptan-insufficient应答,和曲普坦天真。Co-primary疗效端点是自由和没有痛苦最麻烦的migraine-associated症状(MBS) 2 h后初始剂量。不良事件(AEs)历史曲普坦经验子组进行评估。结果:在集中分析人口(n = 1799)、682(安慰剂,n = 350;ubrogepant 50毫克,n = 332), 451(安慰剂,n = 223;ubrogepant, n = 228), 666(安慰剂,n = 339;ubrogepant, n = 327)参与者曲普坦救援人员,triptan-insufficient反应者,和triptan-naive分别。 Response rates on co-primary efficacy endpoints were higher for ubrogepant versus placebo across all groups. Treatment-by-subgroup interaction p values based on odds ratios for pain freedom (p = 0.290) and absence of MBS (p = 0.705) indicated no significant impact of historical triptan experience on ubrogepant efficacy. AE incidence for ubrogepant did not differ appreciably across historical triptan experience subgroups. CONCLUSIONS: Ubrogepant efficacy and tolerability did not differ for the acute treatment of migraine in participants classified as triptan responders, triptan-insufficient responders, and triptan-naive based on their historical experience with triptans.

DrugBank数据引用了这篇文章

药物靶点

药物	目标	类	生物	药理作用	行动
Ubrogepant	降钙素相关基因肽1型受体	蛋白质	人类	是的	拮抗剂	细节